Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
企業コードBBLG
会社名Bone Biologics Corp
上場日Nov 27, 2015
最高経営責任者「CEO」Frelick (Jeffrey)
従業員数2
証券種類Ordinary Share
決算期末Nov 27
本社所在地2 Burlington Woods Dr Ste 100
都市BURLINGTON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号01803-4551
電話番号17815524452
ウェブサイトhttps://www.bonebiologics.com/
企業コードBBLG
上場日Nov 27, 2015
最高経営責任者「CEO」Frelick (Jeffrey)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし